Large Scale Comparative Deconvolution Analysis of the Canine and Human Osteosarcoma Tumor Microenvironment Uncovers Conserved Clinically Relevant Subtypes.
Sushant PatkarJosh MannheimerStephanie HarmonChristina MazckoPeter ChoykeG Tom BrownBaris TurkbeyAmy LeBlancJessica BeckPublished in: bioRxiv : the preprint server for biology (2023)
Osteosarcoma is a relatively rare but aggressive cancer of the bones with a shortage of effective biomarkers. Although less common in humans, Osteosarcomas are fairly common in adult pet dogs and have been shown to share many similarities with their human analogs. In this work, we analyze bulk transcriptomic data of 213 primary and 100 metastatic Osteosarcoma samples from 210 pet dogs enrolled in nation-wide clinical trials to uncover three Tumor Microenvironment (TME)-based subtypes: Immune Enriched (IE), Immune Enriched Dense Extra-Cellular Matrix-like (IE-ECM) and Immune Desert (ID) with distinct cell type compositions, oncogenic pathway activity and chromosomal instability. Furthermore, leveraging bulk transcriptomic data of canine primary tumors and their matched metastases from different sites, we characterize how the Osteosarcoma TME evolves from primary to metastatic disease in a standard of care clinical setting and assess its overall impact on clinical outcomes of canines. Most importantly, we find that TME-based subtypes of canine Osteosarcomas are conserved in humans and predictive of progression free survival outcomes of human patients, independently of known prognostic biomarkers such as presence of metastatic disease at diagnosis and percent necrosis following chemotherapy. In summary, these results demonstrate the power of using canines to model the human Osteosarcoma TME and discover novel biomarkers for clinical translation.
Keyphrases
- endothelial cells
- small cell lung cancer
- squamous cell carcinoma
- clinical trial
- induced pluripotent stem cells
- pluripotent stem cells
- healthcare
- computed tomography
- electronic health record
- transcription factor
- ejection fraction
- gene expression
- newly diagnosed
- pet ct
- rna seq
- positron emission tomography
- extracellular matrix
- molecular docking
- open label
- data analysis
- affordable care act
- artificial intelligence
- chronic pain
- study protocol
- phase iii